StockNote
DP3
Central Pharmaceutical Joint Stock Company 3 (DP3), formerly Central Pharmaceutical Enterprise 3 under the Ministry of Health, was established in 1962. The Company's main activities are the production and trading of pharmaceuticals, chemicals, cosmetics, nutritious foods. The company is producing more than 100 drugs, including products that have confirmed their position at home and abroad such as Golden Star, Complete Negative Kidney, Ginseng Nhung. The company has 03 branches and over 10 exclusive distributors with distribution channels mainly through bidding to supply hospitals across the country. DP3 has been listed and traded on the Hanoi Stock Exchange (HNX) since 2015.
DP3 currently has a market capitalization of roughly VND 1.314 billion, placing it in the mid-cap group on the Vietnamese stock market. Its current P/E of 7,6x is 14% below its own 8-year average (8,8x), suggesting the stock is trading cheaper than its historical norm. P/B stands at 2,2x, 7% below its multi-year average of 2,4x. Return on equity (ROE) is at 30%, up from 28,7% the year before. Its debt-to-equity ratio of 0x is low, reflecting a conservative capital structure. In 2025, revenue grew 5% year-on-year while after-tax profit grew 29%.
This note is generated automatically from the stock's real financial data, for reference only — not investment advice.
Revenue & Profit
Unit: VND billion. Growth (%) vs. previous period.
Market Cap
Unit: VND billion. Year-end values; current year uses latest session.
Debt / Equity
Unit: x. Financial debt over shareholders' equity.
Data aggregated from cafef.vn and VNDirect, for reference only, not investment advice.